CAMBRIDGE, Mass., April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the acceptance of poster presentations for its promising cardiometabolic assets, DA-1241 and DA- 1726, at the EASL Congress 2024 and the American Diabetes Association (ADA) 84th Scientific Sessions in June. "Having multiple posters selected for presentation at two of the most esteemed scientific forums ...